Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
Date:3/10/2009

SAN CARLOS, Calif., March 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Cowen and Company 29th Annual Healthcare Conference in Boston at the Boston Marriott Copley Plaza on Monday, March 16, 2009 at 2:25 p.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until April 1, 2009.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. For more information on Nektar Therapeutics, please visit http://www.nektar.com.

    Nektar Contacts:

    Jennifer Ruddock
    Nektar Therapeutics
    650-631-4954
    jruddock@nektar.com

    Susan Noonan
    The SAN Group
    212-966-3650
    susan@sanoonan.com


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. West Concludes Agreement with Nektar
11. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... July 1, 2015   Neuraltus Pharmaceuticals, Inc. ... of groundbreaking drugs to treat neurodegenerative diseases such ... Robert G. Miller , M.D., Director of the ... California Pacific Medical Center in San Francisco, has been ... $1.5 million to help fund a Phase 2 ...
(Date:7/1/2015)... Isagenix International, a leading global health and ... Silver, and three Bronze Stevie® Awards at the 2015 ... Chicago this month.The American Business Awards ... in the U.S. "Winning is a ... leaders, cultivating talent, creating a unified team, and crafting ...
(Date:7/1/2015)... PHILADELPHIA , July 1, 2015 ... technology will ... s evidence-based clinical s olutions suite ... scientific, technical and medical information products and services, announced today ... -based clinical decision support (CDS) technology company. InferMed,s ...
(Date:7/1/2015)... CONNECTICUT (PRWEB) , ... July 01, 2015 , ... ... or sterilized to combat pathogen transmission. CTI’ new Medical Joysticks have an ... medical devices now have an operator control device that will increase healthcare worker ...
Breaking Biology Technology:Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2
... with Georgetown experts to address biotechnology, science, policy and ethical ... WASHINGTON ... of Health and the Food and Drug Administration outlined a "path ... treatments tailored to match a person,s genetic make-up.  Significant progress in this ...
... ... 2009 Corporate Sustainability Report. , ... Madison, WI USA (PRWEB) June 22, 2010 -- Promega reports significant reductions ... summarizes Promega goals and accomplishments to conserve natural resources, minimize environmental impacts and demonstrate ...
... of researchers from the University of Alberta and the National ... unsealed plastic solar cell, from mere hours to eight months. ... available plastic solar cell technology hit a wall because of ... A chemical coating on an electrode was unstable and migrated ...
Cached Biology Technology:Pebbles Along the 'Path' to Personalized Medicine 2Pebbles Along the 'Path' to Personalized Medicine 3Pebbles Along the 'Path' to Personalized Medicine 4Promega Releases 2009 Corporate Sustainability Report 2
(Date:6/25/2015)... 25, 2015 According to ... (Swipe & Area), Technology, Material (Optical Prism, Piezoelectric, ... Security & Others) & Geography - Global Forecast ... said market is expected to reach $14,500.07 Million ... Browse 76 market Tables and 109 ...
(Date:6/24/2015)... , June 24, 2015 This report ... over the next six years. It contains an analysis ... industry, along with their impact from the short, medium, ... also discusses the industry, market, and technology trends that ... the need of concerned authorities to efficiently manage the ...
(Date:6/23/2015)...   MedNet Solutions , an innovative SaaS-based ... of clinical research, is pleased to announce that ... company,s intuitive, flexible and affordable cloud-based eClinical technology ... Award by the American Business Awards (SM) ... The American Business Awards are considered the nation,s ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... in the August 16th issue of Developmental Cell , ... that guarantees that new blood vessels form in the right ... for a long time that blood vessels branch to give ... our bodies this branching occurs with a reproducible pattern. However, ...
... Institutes have gained new insight into the delicate relationship between ... normal development of stem cells in the heart and may ... news, being announced in a paper published online today in ... the role of stem cells in embryonic heart development, and ...
... MD, August 15, 2011 The American Society of Addiction ... that addiction is a chronic brain disorder and not simply ... sex. This the first time ASAM has taken an official ... use. , When people see compulsive and damaging behaviors ...
Cached Biology News:Gladstone scientists offer new insight into the regulation of stem cells and cancer cells 2Gladstone scientists offer new insight into the regulation of stem cells and cancer cells 3ASAM releases new definition of addiction 2ASAM releases new definition of addiction 3
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
...
... PROTEAN II xi 2-D system runs both gel dimensions ... tube gels can be separated in a single run ... cooling core in much the same manner as the ... the second-dimension slab gels may be cast in the ...
Vitronectin Immunogen: Purified, full length, native human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: